NCT02264613: A trial that was reported late by Aileron Therapeutics, Inc.
This trial has reported, although it was 1342 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02264613 |
|---|---|
| Title | A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 31, 2014 |
| Completion date | March 31, 2020 |
| Required reporting date | March 31, 2021, midnight |
| Actual reporting date | Dec. 2, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 1342 |